Spiro Medical Secures $67 Million Series A Financing to Develop a Neuromodulation System for Asthma

斯皮罗医疗公司获得6700万美元A轮融资，用于开发哮喘神经调节系统

IRVINE, Calif., January 7, 2026-- Spiro Medical, Inc., a Newco established to develop the first of its kind Pulmonary Neuromodulation System (PNM) for the treatment of Asthma announced today the closing of a $67 million Series A equity financing.

加利福尼亚州欧文市，2026年1月7日——Spiro Medical公司（一家为开发首个用于治疗哮喘的肺神经调节系统（PNM）而成立的新公司）今日宣布完成了6700万美元的A轮融资。

The financing included a syndicate of venture investors led by Andera Partners (Paris), Omega Funds (Geneva/Boston) and Sherpa Healthcare Partners (Cayman Islands) and joined by HSG (Hong Kong), Supernova Invest (Paris), Northern Light Venture Capital (Menlo Park, CA) and Hero Inc. Ltd UK which is part of the India-based conglomerate Hero Enterprise..

融资包括由Andera Partners（巴黎）、Omega Funds（日内瓦/波士顿）和Sherpa Healthcare Partners（开曼群岛）领投的财团，HSG（香港）、Supernova Invest（巴黎）、Northern Light Venture Capital（加利福尼亚州门洛帕克）以及隶属于印度Hero Enterprise集团的Hero Inc. Ltd UK也参与其中。

Proceeds from the financing will be used to develop a purpose-built PNM system and to execute on the clinical work required for regulatory approval in the United States.

融资所得将用于开发专用的PNM系统，并执行美国监管批准所需的临床工作。

'I am delighted to welcome world-class venture capital investors who understand the immense potential of this PNM technology. Once this novel approach comes to market, it promises to have a profound impact on patients suffering from Asthma and other breathing related conditions,' said Raymond W. Cohen, chairman of the board of directors..

“我非常高兴地欢迎了解这种PNM技术巨大潜力的世界级风险资本投资者。这种新颖的方法一旦上市，必将对哮喘和其他呼吸相关疾病的患者产生深远的影响，”董事会主席雷蒙德·W·科恩表示。

Spiro Medical also welcomed Raphaël Wisniewski of Andera, Claudio Nessi of Omega and Ouyang Xiangyu of Sherpa to its board of directors.

斯皮罗医疗公司还欢迎安德烈的拉斐尔·维尼奥夫斯基、欧米茄的克劳迪奥·内西和夏尔巴的欧阳翔宇加入其董事会。

Mr. Rinda Sama, CEO of Spiro Medical, said, 'We are grateful to our co-founder Stephen Pyles M.D., for his foresight and look forward to his future contributions. We believe this is a rather unique opportunity to be starting a project with issued patents and some human data which informs us about the potential for this exciting new clinical indication for neuromodulation.

斯皮罗医学公司首席执行官林达·萨玛先生表示：“我们感谢联合创始人斯蒂芬·派尔斯医学博士的远见卓识，并期待他未来的贡献。我们认为这是一个非常独特的机遇，能够从已颁发的专利和一些人体数据开始一个项目，这些数据向我们展示了这种令人兴奋的神经调节新临床应用的潜力。”

We are also highly confident that we can build a world-class system given our team's experience and expertise in developing implantable neuromodulation systems.'.

我们也有高度的信心，可以建立一个世界级的系统，因为我们团队在开发可植入神经调节系统方面有经验和技术。

About Asthma

关于哮喘

Asthma is a common chronic lung disease, affecting over 28 million Americans and over 300 million people worldwide. Many clinical symptoms of asthma are related to the nervous system and can be at least partially attributed to altered activation or regulation of airway nerves. Associated symptoms such as wheezing, shortness of breath, chest tightness and coughing, etc., are mediated in part, by targeting these neural reflex pathways..

哮喘是一种常见的慢性肺部疾病，影响着超过2800万美国人和全球超过3亿人。哮喘的许多临床症状与神经系统有关，至少可以部分归因于气道神经的激活或调节改变。相关的症状如喘息、呼吸急促、胸闷和咳嗽等，部分是通过针对这些神经反射通路介导的。

About Spiro Medical

关于Spiro Medical

Spiro Medical, based in Irvine, CA is a new company founded by Stephen Pyles, M.D., Kurt Gehlsen, M.D., Ph.D., Rinda Sama and G. Jay Jiang, Ph.D. with the purpose of developing a purpose-built Pulmonary Neuromodulation System to treat patients suffering from severe Asthma.

斯皮罗医学公司位于加利福尼亚州欧文市，是一家新成立的公司，由斯蒂芬·派尔斯医学博士、库尔特·格勒森医学博士、哲学博士、林达·萨玛和姜杰伊哲学博士共同创立，旨在开发一种专门用于治疗严重哮喘患者的肺神经调节系统。